---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-065890"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T15:34:31.637435+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics raises $18.5M, advances lead asset stenoparib, reports early IXEMPRA tumor shrinkage data

## Summary
- Raised $18.5M in new investment capital since January 2023 to fund clinical programs.
- Initiated Phase 1b/2 combination study of stenoparib + dovitinib in early 2023.
- IXEMPRA Phase 2 in Europe shows early signs of tumor shrinkage and stable disease in metastatic breast cancer.
- Stenoparib is now lead clinical asset; advancing in two of three ongoing trials.
- Entered clinical collaboration with FivepHusion for Deflexifol using 5FU-DRP CDx.

## SEC filing metadata
- accession: 0001213900-23-065890
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023065890/0001213900-23-065890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023065890/ea183319-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-065890
- JSON: https://secwatch.observer/filing/0001213900-23-065890.json
- Plain text: https://secwatch.observer/filing/0001213900-23-065890.txt

## Key facts
- Executive change
  Robert Oliver resigned as director at Allarity Therapeutics, Inc..
  - Action: resigned
  - Role: director
  source text: On August 7, 2023, the Board of Directors (the “Board”) of Allarity Therapeutics, Inc. (the “Company”) received the resignation of Mr. Robert Oliver as director of the Company, including his position on each Board committee on which he was appointed to, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023065890/0001213900-23-065890-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.